MedPath
EMA Product

Nyxoid

Product approved by European Medicines Agency (EU)

Basic Information

Nyxoid

Regulatory Information

EMEA/H/C/004325

Authorised

November 9, 2017

9

February 24, 2023

Company Information

Ireland

United Drug House Magna Drive Magna Business Park Citywest Road Dublin 24

MUNDIPHARMA CORPORATION (IRELAND) LIMITED

Active Substances Detail

Naloxone hydrochloride dihydrate

Detailed Information

Therapeutic Indication

### Therapeutic indication Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Nyxoid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nyxoid. For practical information about using Nyxoid, patients should read the package leaflet or contact their doctor or pharmacist.

© Copyright 2025. All Rights Reserved by MedPath